Liquid biopsy startup Grail Inc. said it has raised more than $900 million through the first close of its series B round, putting it on the path to develop a blood-based test for cancer screening. The Menlo Park, Calif.-based company is slated to bring in more than $1 billion in the round and could close on the remainder of the investment prior to the end of 1Q17.

Liquid biopsy startup Grail Inc. said it has raised more than $900 million through the first close of its series B round, putting it on the path to develop a blood-based test for cancer screening. The Menlo Park, Calif.-based company is slated to bring in more than $1 billion in the round and could close on the remainder of the investment prior to the end of the first quarter.

Viewray Inc. received FDA clearance for the Mridian Linac system, a device that allows clinicians to visualize in real time the movement of tumors and organs during radiation treatment. The Oakwood, Ohio-based company's technology, which also has CE mark approval, combines MRI guidance with linear accelerator radiation. Viewray's president and CEO, Chris Raanes called the clearance a milestone for the company. First-generation Mridian technology, which uses cobalt-60 therapy for therapy, received FDA clearance back in 2012. (See Medical Device Daily, May 31, 2012.) "We spent an awful lot of time explaining to the world why...

Viewray Inc. received FDA clearance for the Mridian Linac system, a device that allows clinicians to visualize in real time the movement of tumors and organs during radiation treatment. The Oakwood, Ohio-based company's technology, which also has CE mark approval, combines MRI guidance with linear accelerator radiation.

Cagent Vascular LLC. has received FDA clearance for its Serranator Alto PTA serration balloon catheter. The Wayne, Pa.-based company's device is the first of a family of peripheral artery disease (PAD) technologies under development which incorporate the company's serration technology in an angioplasty balloon. The private company's device is indicated for dilatation of lesions in the iliac, femoral, iliofemoral and popliteal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. "The whole concept behind the Serranator Alto PTA device is to create these longitudinal lines of interrupted micro serration,"...

Cagent Vascular LLC. has received FDA clearance for its Serranator Alto PTA serration balloon catheter. The Wayne, Pa.-based company's device is the first of a family of peripheral artery disease (PAD) technologies under development which incorporate the company's serration technology in an angioplasty balloon.

Boston Scientific Corp. said it was recalling its previous generation Lotus heart valve replacement devices following reports of problems with the products' locking mechanisms. The Marlborough, Mass.-based company said the issue stems from excess tension in the pin mechanism that was introduced during the manufacturing process. News of the recall caused the devicemaker's (NYSE:BSX) shares to temporarily plummet by 8 percent on Thursday morning. By closing the shares were down about 2.68 percent, closing at $24.48. Boston Scientific spokeswoman, Timette Nevala, told Medical Device Daily, that Thursday's recall was a "result of a number of...

Boston Scientific Corp. said it was recalling its previous generation Lotus heart valve replacement devices following reports of problems with the products' locking mechanisms. The Marlborough, Mass.-based company said the issue stems from excess tension in the pin mechanism that was introduced during the manufacturing process.

Medtronic plc revealed strong 3Q17 sales in its most recent earnings, distancing itself from a relatively bleak 2Q17. The Dublin-based company's revenue grew about six percent during the three months ending on Jan. 27 compared to the same period last year. Strong sales also boosted Medtronic's adjusted income up 3.3 percent to $1.5 billion, on total sales of $7.28 billion during the quarter. With these earnings the company is rebounding from a period of stalled growth. "The 6 percent growth in the quarter dispelled some of the concerns that last quarter's 3 percent, including 1...